Telstra Corporation: Under the hood it’s looking good
About the author:
- Author name:
- By Nick Harris
- Job title:
- Senior Analyst
- Date posted:
- 18 February 2022, 9:00 AM
- Sectors Covered:
- Telecommunications, Technology
- Telstra Corporation's (ASX:TLS) 1H22 result showed the second consecutive half of underlying growth, with underlying EBITDA up 5%, underlying EPS up substantially and the DPS flat YoY. Reported numbers dipped YoY due to lower NBN revenue and other one-off gains (which boosted 1H21 reported numbers). Mobile was the star performer.
- Performance is tracking in the right direction and FY22 guidance was re-iterated.
- We make minor EPS upgrades on lower D&A; retain Add and (login to view) target price.
Event - 1H22 result
TLS’s 1H22 result showed the second consecutive half of underlying growth, as expected. Underlying EBITDA was up ~5% to $3.5bn and underling EPS grew an impressive 55% to 6.2cps. Underlying EPS now exceeds underlying DPS.
Reported Revenue, EBITDA and EPS were all down YoY. Reported numbers were negatively impacted by a decline in the number of one-offs (which boosted 1H21 numbers) combined with a ~70% YoY decline in one-off NBN payments.
The Board declared an 8cps dividend (6c ordinary + 2c special).
The result was slightly better than our forecasts at the EPS line largely due to lower D&A.
A reiteration of FY22 guidance suggests all is going to plan.
Analysis - result inline to slightly better than our forecasts and trending well
As expected mobile, which accounted for 56% of 1H22 underlying EBITDA, was the star performer. Mobile services revenue was up ~6% YoY while mobile EBITDA was up an impressive 25% YoY on service revenue growth and cost savings.
Mobile margins expanded materially (900bps YoY). Some of this is temporary (e.g. less low margin handset sales due to supply chain challenges). However this result also shows the significant positive operating leverage on offer when subscribers and ARPU grow.
Mobile revenue growth is attributed to adding subscribers and increasing ARPU by ~5%. TMMC up $2 in 1H22. TLS’s 5G dominance is apparent in this result and should remain apparent for the next few years. Accounting changes mean ARPU is unlikely to grow in 2H22 (on a stat basis, but normalised ARPU will still grow).
The ordinary dividend increased from 5 to 6cps. Total dividends were flat YoY at 8cps. However, ordinary eps increased from 4.0 to 6.2c and now covers the ordinary dividend. The total div payout ratio is ~140% of EPS and ~60% of FCF.
Forecast and valuation update
With guidance reiterated, we have made no meaningful change to our FY22 EBITDA forecasts. We have, however, marginally increased our operating expenses in FY23 which decreases our EBITDA by 3%.
Offsetting this our EPS forecast lifts on lower depreciation and amortisation. Management guided for D&A to be broadly flat HoH. Given capex sits materially lower than D&A, and ignoring new large infrastructure projects, D&A should progressively decline. This lower D&A flows into FY22 and FY23, lifting our NPAT and EPS forecasts by ~5% and ~11% respectively.
We retain our Add recommendation and (login to view) target price.
Add retained. Sector dynamics look positive and value realisation is possible.
Proof points supporting industry rationality (ARPU rises sticking and FCF growing).
SOTP realisation (new business units track record, partial divestments, and full divestments of small holdings eg the potential IPO of Foxtel).
Key risks relate to industry pricing remaining rationale and realisation of value drivers.
Find out more
Download full research note
You can find further detailed analysis of company results this reporting season by browsing our reporting season tag, and view a full list of upcoming results on our Reporting Season Calendar.
If you would like access or more information, please contact your adviser or nearest Morgans office.
Request a call
Find local branch
Need access to our research?
You are also welcome to start a two-week trial of our online platform, which provides access to detailed market analysis and insights, provided by our award-winning research team.
Create trial account
Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.